ArticleAmerican journal of translational research2026
Risk factors for cognitive dysfunction in prostate cancer patients undergoing androgen deprivation therapy: a retrospective study.
Article in American journal of translational research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo evaluate the clinical efficacy of endocrine therapy for prostate cancer and analyze risk factors for treatment-related cognitive dysfunction.
methodsA retrospective study was conducted involving 100 prostate cancer patients receiving endocrine therapy and 100 non-recipients. Quality of life, urinary symptoms, and cognitive function were assessed. Patients were categorized into cognitive dysfunction (n=38) and non-dysfunction (n=62) groups based on post-treatment assessment. Univariate and multivariate analyses were used to identify influencing factors, and a predictive model was developed.
resultsThe endocrine therapy group showed significantly better quality of life and urinary symptom scores (all P < 0.05), though the 5-year survival rate was lower than that of the control group (72.4% vs 82.7%). Cognitive impairment incidence was 38%. Risk factors included older age, lower education, lower Montreal Cognitive Assessment (MoCA) scores, and higher Prostate-Specific Antigen (PSA), Self-Rating Anxiety Scale (SAS), and Self-Rating Depression Scale (SDS) scores (all P < 0.05). Multivariate analysis confirmed MoCA, age, SAS, and SDS as independent predictors. The predictive model demonstrated high discriminative ability (AUC=0.903).
conclusionEndocrine therapy improves quality of life and urinary symptoms in prostate cancer patients but is associated with cognitive dysfunction. A model incorporating MoCA, age, and psychological scores effectively predicts cognitive impairment risk, enabling targeted intervention.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.